Related Experiment Video
Updated: Jul 23, 2025
04:46
Optimizing Isolation and Purification of Murine Glomerular Mesangial Cells
Published on: March 7, 2025
334
Contemporary Monoclonal Antibody Utilization in Glomerular Diseases
Iyad Mansour1, Sangeetha Murugapandian1, Bekir Tanriover1
1Division of Nephrology, College of Medicine, The University of Arizona, Tucson.
Mayo Clinic Proceedings. Innovations, Quality & Outcomes
|July 14, 2023
Summary
Therapeutic monoclonal antibodies (MAbs) offer targeted treatment for glomerular diseases, showing high specificity and low toxicity. This review highlights their evolving role in personalized medicine and immune-mediated conditions.
Area of Science:
- Immunology
- Pharmacology
- Nephrology
Background:
- Therapeutic monoclonal antibodies (MAbs) represent a rapidly expanding drug class, approved for various conditions including cancer, autoimmune disorders, and glomerular diseases.
- MAbs constitute 20% of annual FDA new drug approvals, favored for their specificity, reduced drug interactions, and low toxicity, aligning with personalized medicine principles.
Purpose of the Study:
- To provide a comprehensive overview of the taxonomy, pharmacology, and therapeutic applications of monoclonal antibodies in glomerular diseases.
- To review recent advancements and the current evidence base for MAb utilization in treating immune-mediated glomerular diseases.
Main Methods:
- Literature search conducted on PubMed using keywords: monoclonal antibodies, glomerular diseases, pharmacokinetics, pharmacodynamics, immunoglobulin, murine, chimeric, humanized, and fully human.
- Search limited to peer-reviewed articles published between 2018 and 2023, prioritizing randomized controlled trials for evidence-based review.
Main Results:
- Monoclonal antibodies have significantly advanced the targeted treatment of immune-mediated glomerular diseases.
- Multiple ongoing randomized control trials indicate a paradigm shift towards MAb-based therapies in nephrology.
Conclusions:
- Monoclonal antibodies are crucial in modern therapeutics for glomerular diseases, offering a personalized medicine approach.
- Further research and recognition are essential to expand the use of MAbs in experimental settings and clinical practice for these conditions.
More Related Videos
Related Concept Videos
01:31Hybridoma Technology
15.0K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
15.0K
01:28Chronic Kidney Disease III: Interprofessional Care
43
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
43
01:02Renal Drug Excretion: Glomerular Filtration
328
The kidney serves as the primary organ responsible for eliminating drugs and their metabolites from the body. This process, known as renal elimination, starts with glomerular filtration and results in urine formation. Each kidney houses millions of functional units called nephrons, where urine production occurs. A nephron has two main components: a renal corpuscle and a renal tubule.
Drugs gain access to the kidney via the renal artery, which progressively branches off into afferent arterioles....
Drugs gain access to the kidney via the renal artery, which progressively branches off into afferent arterioles....
328
01:20Renal Corpuscle
2.8K
The glomerulus and Bowman's capsule are two essential components of the nephron, which is the functional unit of the kidney. These microscopic structures play a critical role in the process of blood filtration to produce urine.
Glomerulus: Structure and Function
The glomerulus is a tiny, intricate network of capillaries located at the beginning of the nephron. It's enveloped by the Bowman's capsule and receives its blood supply from an afferent arteriole, which divides into numerous...
Glomerulus: Structure and Function
The glomerulus is a tiny, intricate network of capillaries located at the beginning of the nephron. It's enveloped by the Bowman's capsule and receives its blood supply from an afferent arteriole, which divides into numerous...
2.8K
01:26Nephrotic Syndrome II : Assessment and Medical Management
8
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document...
8
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
175
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
175